CKD: The Complete Patient's Guide to Chronic Kidney Disease Stages, Diagnosis, and Long-Term Management
What Does "CKD" Mean? Understanding the Term and Its Significance
CKD stands for chronic kidney disease — a term that encompasses a broad spectrum of conditions characterized by persistent abnormalities in kidney structure or function lasting more than three months. The word "chronic" is critical: it distinguishes this group of conditions from acute kidney injury (AKI), which is a sudden, potentially reversible decline in kidney function. Chronic kidney disease, by definition, involves permanent structural damage and/or sustained loss of kidney function that, once established, cannot be fully reversed.
The significance of CKD extends far beyond the kidneys themselves. CKD is a systemic disease that affects cardiovascular health, bone metabolism, hormonal regulation, neurological function, and quality of life. It is a major global public health challenge: the Global Burden of Disease study estimates that CKD caused 1.2 million deaths in 2017, and its global prevalence is approximately 9.1% of the world's adult population — around 700 million people. In the United States, CKD affects approximately 37 million adults and is the 8th leading cause of death.
Despite its prevalence and impact, CKD remains dramatically underdiagnosed and undertreated. An estimated 90% of people with CKD are unaware they have the condition. This "silent epidemic" aspect of CKD — its ability to progress for years without causing obvious symptoms — makes understanding, screening for, and managing CKD a priority for patients, healthcare providers, and public health officials alike. For a complete contextual understanding of chronic kidney disease, including its causes and full impact on the body, see our comprehensive overview guide.
The CKD Staging System: Understanding the Five Stages
The modern CKD staging system was established by the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDOQI) in 2002 and subsequently refined by the international KDIGO (Kidney Disease: Improving Global Outcomes) guidelines in 2012. The staging system classifies CKD based on two key parameters: the estimated glomerular filtration rate (eGFR) and the degree of albuminuria (protein in the urine). Together, these two measures provide a comprehensive picture of both the level of kidney function and the degree of kidney damage.
The five CKD stages by eGFR are as follows. Stage 1 (eGFR ≥ 90 mL/min/1.73m²) represents kidney damage with normal or near-normal function — the kidneys are filtering adequately but there is evidence of structural damage, most commonly detected by the presence of albumin in the urine. The vast majority of Stage 1 patients have absolutely no symptoms and feel completely well. Stage 2 (eGFR 60–89 mL/min/1.73m²) is mildly decreased function — again, essentially asymptomatic in almost all cases, and often discovered on routine bloodwork performed for other reasons.
Stage 3 is divided into 3a (eGFR 45–59 mL/min/1.73m²) and 3b (eGFR 30–44 mL/min/1.73m²), representing moderate decrease in kidney function. This is the most common stage at which CKD is diagnosed, and when treatment can be most impactful in slowing progression. Some patients begin to experience fatigue, mild swelling, or elevated blood pressure, but many are still asymptomatic. Stage 4 (eGFR 15–29 mL/min/1.73m²) is severe loss of kidney function — at this stage, symptoms become more prominent, complications of CKD are common, and planning for kidney replacement therapy (dialysis or transplant) must begin. Stage 5 (eGFR < 15 mL/min/1.73m²) is kidney failure, also known as end-stage kidney disease (ESKD). For a comprehensive discussion of what happens at this final stage, including treatment options, see our guide on chronic renal failure.
The Role of Albuminuria in CKD Classification
The KDIGO classification system added albuminuria as a second dimension to CKD staging, recognizing that albuminuria is an independent predictor of CKD progression and cardiovascular risk, over and above the eGFR. Albuminuria is measured using the urine albumin-to-creatinine ratio (uACR) in a spot urine sample, expressed in mg/g (or mg/mmol).
The three albuminuria categories are A1 (uACR < 30 mg/g — normal to mildly increased), A2 (uACR 30–300 mg/g — moderately increased, previously called "microalbuminuria"), and A3 (uACR > 300 mg/g — severely increased, previously called "macroalbuminuria" or "proteinuria"). The combination of eGFR stage and albuminuria category creates a risk matrix that guides the intensity of monitoring and treatment. A patient with Stage 3a CKD and A3 albuminuria has a much higher risk of progression and cardiovascular events than a patient with Stage 3a and A1 albuminuria — and requires more aggressive management accordingly.
Albuminuria is also important because it often appears before eGFR begins to decline — making it an early marker of kidney damage that enables earlier diagnosis and treatment. In diabetic nephropathy, for example, microalbuminuria typically precedes macro-albuminuria by years, which in turn precedes significant eGFR decline. Screening for albuminuria in high-risk populations (diabetics, hypertensives, elderly, those with family history of CKD) is one of the most cost-effective strategies for early CKD detection.
How CKD Is Diagnosed: Tests and Procedures
CKD diagnosis relies on laboratory tests and imaging to confirm reduced kidney function and/or damage, identify the underlying cause, and assess the severity of complications. The diagnosis requires two measurements of eGFR below 60 mL/min/1.73m² and/or evidence of kidney damage at least 3 months apart — this "three month" criterion distinguishes chronic disease from acute kidney injury.
The eGFR is derived from the serum creatinine level, along with age and sex (and historically, race — though race-adjusted equations have been phased out of many guidelines due to concerns about their equity implications). The CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation is the most widely recommended formula for eGFR calculation. Some centers also use cystatin C, a different blood marker of kidney function, to confirm or refine the eGFR estimate — the combined creatinine-cystatin C eGFR is considered the most accurate estimate of true GFR.
The urine albumin-to-creatinine ratio (uACR) is the recommended test for detecting and quantifying albuminuria. While early guidelines recommended 24-hour urine protein collections, spot uACR measurements are more practical and equally valid for most clinical purposes. Urine dipstick testing can also detect proteinuria but is less sensitive and cannot distinguish albumin from other proteins.
Additional blood tests include BUN (blood urea nitrogen), electrolytes (sodium, potassium, chloride, bicarbonate, calcium, phosphorus), complete blood count (for anemia assessment), parathyroid hormone, vitamin D levels, uric acid, and lipid profile. Renal ultrasound is performed in most patients at the time of CKD diagnosis to assess kidney size (small kidneys suggest chronic disease), identify structural abnormalities (cysts, hydronephrosis, masses), and evaluate blood flow. Kidney biopsy is performed selectively — when the underlying cause of CKD is unclear and identifying it would change management, or when the rate of progression is unexpectedly rapid.
CKD Management at Stages 1–2: Early Intervention and Risk Factor Control
In Stages 1 and 2 CKD, the primary management goals are to identify and treat the underlying cause, aggressively control modifiable risk factors (especially blood pressure and blood sugar), and reduce albuminuria to the lowest achievable level. At these stages, it is often possible to stabilize or even slightly improve eGFR with excellent treatment, though complete restoration of damaged nephrons is not possible.
For patients with diabetic kidney disease, the current standard of care involves optimization of glycemic control (targeting HbA1c in the range of 6.5–7.5% in most patients), aggressive blood pressure control (targeting below 130/80 mmHg), use of ACE inhibitors or ARBs (which reduce proteinuria and have nephroprotective effects independent of blood pressure lowering), and the addition of SGLT2 inhibitors such as empagliflozin, dapagliflozin, or canagliflozin, which have demonstrated remarkable renal and cardiovascular protective effects in clinical trials. Finerenone, a novel non-steroidal mineralocorticoid receptor antagonist, also has recently demonstrated significant nephroprotection in Type 2 diabetic CKD.
For patients with hypertensive CKD, achieving target blood pressure is the primary intervention. ACE inhibitors or ARBs are preferred as first-line agents due to their dual anti-hypertensive and nephroprotective properties. In patients with significant proteinuria, these agents should be used even if blood pressure is normal. Lifestyle modifications — dietary sodium restriction (less than 2,300 mg/day), weight loss, physical activity, and smoking cessation — are integral components of management at all CKD stages.
Frequency of monitoring is important and should be guided by the patient's CKD stage and albuminuria category. At Stage 1–2 with A1 albuminuria, annual monitoring may suffice. At higher-risk stages and albuminuria categories, more frequent monitoring (every 3–6 months) is appropriate to catch worsening of kidney function or complications early.
Managing CKD at Stage 3: Preventing Progression and Complications
Stage 3 is the inflection point in CKD management — the stage at which a structured, multidisciplinary approach becomes essential and the risk of both progression and complications rises substantially. In addition to the risk factor control strategies described above, Stage 3 management must address the emerging complications of kidney function decline.
Anemia is increasingly common from Stage 3 onwards, as the kidneys produce less erythropoietin. The target hemoglobin in CKD patients is generally 10–11.5 g/dL — enough to alleviate symptoms without reaching levels associated with increased cardiovascular risk. Treatment involves iron replacement (intravenous iron is often more effective than oral in CKD, as intestinal iron absorption is impaired) and, when necessary, erythropoiesis-stimulating agents (ESAs such as darbepoetin alfa or epoetin alfa). Before initiating ESAs, iron deficiency must be corrected — the two are complementary therapies.
Mineral and bone disease begins to emerge in Stage 3. Rising phosphorus, falling calcium, vitamin D deficiency, and secondary hyperparathyroidism constitute the CKD-mineral and bone disorder (CKD-MBD). Management involves dietary phosphate restriction, phosphate binders (calcium carbonate, sevelamer, lanthanum carbonate) to reduce gut phosphate absorption, active vitamin D supplementation (calcitriol or alfacalcidol) to improve calcium absorption and suppress PTH, and regular monitoring of the PTH-calcium-phosphate axis. Maintaining normal mineral levels dramatically reduces the risk of vascular calcification and cardiovascular events.
Metabolic acidosis — lower-than-normal blood bicarbonate — is associated with more rapid CKD progression (acidosis itself impairs kidney function and accelerates tubular atrophy), muscle wasting, and bone disease. Oral sodium bicarbonate supplementation, titrated to maintain serum bicarbonate above 22 mEq/L, is recommended and has been shown in clinical trials to slow CKD progression.
Stage 4 CKD: Preparing for Renal Replacement Therapy
By Stage 4 (eGFR 15–29 mL/min/1.73m²), the focus of management shifts significantly. While all the therapeutic strategies described above continue, a major additional priority is preparing the patient — physically, practically, and emotionally — for renal replacement therapy. Waiting until symptoms are severe or eGFR drops to dangerously low levels before initiating this preparation leads to worse outcomes, more emergency dialysis starts (which are associated with significantly worse long-term outcomes than planned initiations), and worse quality of life.
Education about dialysis modalities (hemodialysis versus peritoneal dialysis) and kidney transplantation should begin in Stage 4. This allows the patient time to research, visit dialysis centers, meet other patients, and make an informed decision. If the patient is a transplant candidate and has living potential donors, evaluation of both the patient and donors can be initiated while the patient is still in Stage 4, potentially allowing a preemptive transplant (before dialysis is needed) — which is associated with the best long-term outcomes.
For patients choosing hemodialysis, vascular access creation must be planned well in advance. An AV fistula should ideally be created 6–12 months before anticipated dialysis need to allow adequate maturation time. Referral to vascular surgery for fistula creation is an important Stage 4 management action.
Medication management in Stage 4 requires careful review of all drugs for dose adjustments, as many medications are renally cleared and can accumulate to toxic levels in advanced CKD. Nephrotoxic drugs (NSAIDs, certain antibiotics, contrast agents) should be avoided or used with extreme caution. Metformin, a key diabetes drug, is contraindicated when eGFR falls below 30 mL/min/1.73m² due to risk of lactic acidosis.
New and Emerging Therapies in CKD Management
The last decade has been transformative in CKD management, with several novel drug classes demonstrating significant nephroprotective and cardioprotective effects in large, well-designed randomized controlled trials. These advances have substantially changed the standard of care, particularly for patients with diabetic kidney disease and heart failure with CKD.
SGLT2 inhibitors (sodium-glucose cotransporter-2 inhibitors) represent the most significant advance in nephrology in decades. Originally developed as glucose-lowering agents for type 2 diabetes, they work in the kidney by blocking the reabsorption of glucose and sodium in the proximal tubule, leading to glucosuria and natriuresis. Beyond their metabolic effects, they reduce intraglomerular pressure (through tubuloglomerular feedback mechanisms), decrease proteinuria, reduce inflammation and fibrosis, and improve kidney oxygenation. The CREDENCE trial (canagliflozin), DAPA-CKD trial (dapagliflozin), and EMPA-KIDNEY trial (empagliflozin) have all demonstrated significant reductions in the composite kidney endpoint (doubling of creatinine, ESKD, or kidney death) by 30–40% in CKD patients. Notably, the benefits in DAPA-CKD and EMPA-KIDNEY extended to non-diabetic CKD patients as well, broadening the indication far beyond diabetes.
GLP-1 receptor agonists (glucagon-like peptide-1 receptor agonists), primarily developed for diabetes management and cardiovascular risk reduction, are now demonstrating kidney-protective effects in trials like FLOW (semaglutide) and may become an additional therapeutic option for CKD patients with or without diabetes. Finerenone, a selective non-steroidal mineralocorticoid receptor antagonist, has demonstrated significant reductions in CKD progression and cardiovascular events in two major trials (FIDELIO-DKD and FIGARO-DKD) in patients with type 2 diabetes and CKD.
Multidisciplinary CKD Care: The Team Approach
Optimal CKD management requires a coordinated team of specialists. The nephrologist leads the team in managing kidney-specific issues, but the complexity of CKD means that other specialists play crucial roles. The cardiologist manages the high burden of cardiovascular disease. The diabetologist or endocrinologist optimizes metabolic control in diabetic patients. The renal dietitian provides individualized dietary guidance at each stage of disease. The renal nurse or case manager coordinates care, provides education, and ensures medication adherence. The social worker addresses the psychosocial and financial challenges of living with CKD. The palliative care specialist supports patients facing end-stage disease decisions.
The multidisciplinary clinic model — where patients see multiple specialists in a single visit — has been shown in multiple studies to improve outcomes in CKD, including slower progression rates, fewer emergency dialysis starts, and better quality of life. Patients with Stage 3b–4 CKD should ideally be managed in dedicated CKD multidisciplinary clinics at nephrology centers with the expertise and resources to provide this level of care.
For patients wanting to understand what symptoms to watch for that may indicate CKD progression, our article on CKD symptoms and early warning signs provides detailed, clinically accurate information. And for those concerned about the advanced stages of CKD and what kidney failure treatment options are available, our comprehensive guide to chronic renal failure covers everything you need to know about end-stage kidney disease management.